Updated data from a Phase 1 clinical trial assessing BeiGene's (BGNE+2.6%) PD-1 inhibitor BGB-A317 in patients with advanced solid tumors showed greater than a 38% disease control rate. The results were presented at the Society for Immunotherapy of Cancer 31st Annual Meeting in National Harbor, MD.
In 99 evaluable patients as of September 30, 15 (15%) were partial responders and 23 (23%) had stable disease implying a disease control rate of 38%. 87% (n=13/15) of the partial responders remain on treatment with duration of response ranging from 28 - 47 weeks. Responders include renal cell carcinoma, urothelial carcinoma, gastric cancer, Merkel cell carcinoma, naospharyngeal cancer and penis squamous cell carcinoma an duodenal carcinoma.
The most common treatment-related adverse events (TRAEs) were fatigue (19%), diarrhea (13%), rash (11%), pruritis (11%), nausea (8%), hypothyroidism (7%) and infusion-related reactions (6%).
The study will advance to a 1b phase during which flat dosing of 200 mg and 300 mg every three weeks will be explored.